Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Mallinckrodt
Boehringer Ingelheim
McKesson
Dow

Last Updated: March 22, 2023

Investigational Drug Information for Delamanid


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Delamanid?

Delamanid is an investigational drug.

There have been 24 clinical trials for Delamanid. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2020.

The most common disease conditions in clinical trials are Tuberculosis, Tuberculosis, Multidrug-Resistant, and Tuberculosis, Pulmonary. The leading clinical trial sponsors are Otsuka Pharmaceutical Development & Commercialization, Inc., National Institute of Allergy and Infectious Diseases (NIAID), and Harvard Medical School.

There are nine US patents protecting this investigational drug and two hundred and eighty-nine international patents.

Recent Clinical Trials for Delamanid
TitleSponsorPhase
Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TBHaitian Group for the Study of Kaposi's Sarcoma and OpportunisticPhase 2
Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TBHarvard School of Public Health (HSPH)Phase 2
Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TBUniversity of California, Los AngelesPhase 2

See all Delamanid clinical trials

Clinical Trial Summary for Delamanid

Top disease conditions for Delamanid
Top clinical trial sponsors for Delamanid

See all Delamanid clinical trials

US Patents for Delamanid

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Delamanid See Plans and Pricing Nitroimidazooxazine and nitroimidazooxazole analogues and their uses Global Alliance for TB Drug Development (New York, NY) See Plans and Pricing
Delamanid See Plans and Pricing Pharmaceutical composition achieving excellent absorbency of pharmacologically active substance Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP) See Plans and Pricing
Delamanid See Plans and Pricing Antituberculous composition comprising oxazole compounds Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP) See Plans and Pricing
Delamanid See Plans and Pricing Nitroimidazooxazines and their uses in anti-tubercular therapy Global Alliance for TB Drug Development (New York, NY) See Plans and Pricing
Delamanid See Plans and Pricing Imidazo [1,2-a]pyridine compounds, synthesis thereof, and methods of using same UNIVERSITY OF NOTRE DAME DU LAC (Notre Dame, IN) See Plans and Pricing
Delamanid See Plans and Pricing Combination therapy to treat Mycobacterium diseases SPERO TRINEM, INC. (Cambridge, MA) See Plans and Pricing
Delamanid See Plans and Pricing 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles and a process for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (New Delhi, IN) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Delamanid

Drugname Country Document Number Estimated Expiration Related US Patent
Delamanid China CN107406386 2035-03-27 See Plans and Pricing
Delamanid Eurasian Patent Organization EA201792154 2035-03-27 See Plans and Pricing
Delamanid European Patent Office EP3275862 2035-03-27 See Plans and Pricing
Delamanid Japan JP6776226 2035-03-27 See Plans and Pricing
Delamanid Japan JPWO2016158737 2035-03-27 See Plans and Pricing
Delamanid South Korea KR20170129898 2035-03-27 See Plans and Pricing
Delamanid Lithuania LT3275862 2035-03-27 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Mallinckrodt
Boehringer Ingelheim
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.